United Therapeutics Corporation (UTHR)

Every figure this model derived for UTHR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 592,200,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 2,662,300,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 3,483,700,000 AssetsCurrent 2026-06-30
current liabilities 607,800,000 LiabilitiesCurrent 2026-06-30
equity 6,400,300,000 StockholdersEquity 2026-06-30
interest expense 12,000,000 InterestExpenseNonoperating 2026-06-30
ocf 1,685,200,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,154,500,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 155,400,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up UTHR on one particular measure came for.

RatioValue
cash operating margin52.27
current ratio5.73
current ratio reported5.73
dilution pct-1.24
ebit cagr10.79
ebit yoy-3.2
fcf margin34.65
growth cv0.28
interest cover116.82
operating margin44.44
owner earnings margin29.72
revenue growth2.49
revenue growth per share3.78
roic29.63
rule of 4046.93
sbc pct revenue4.93

What to be careful about

What this model itself distrusts about UTHR's figures. Written by the derivation as it ran, not added afterwards.